4C3 Human Monoclonal Antibody: A Proof of Concept for Non-pathogenic Proteinase 3 Anti-neutrophil Cytoplasmic Antibodies in Granulomatosis With Polyangiitis.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 15 06 2020
accepted: 01 09 2020
entrez: 26 10 2020
pubmed: 27 10 2020
medline: 16 6 2021
Statut: epublish

Résumé

Granulomatosis with polyangiitis (GPA) is a severe autoimmune vasculitis associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCA) mainly targeting proteinase 3 (PR3), a neutrophilic serine proteinase. PR3-ANCA binding to membrane-bound PR3 on neutrophils induce their auto-immune activation responsible for vascular lesions. However, the correlation between PR3-ANCA level and disease activity remains inconsistent, suggesting the existence of non-pathogenic PR3-ANCA. In order to prove their existence, we immortalized B lymphocytes from blood samples of GPA patients in remission having persistent PR3-ANCA to isolate non-activating PR3-ANCA. We obtained for the first time a non-activating human IgG1κ anti-PR3 monoclonal antibody (mAb) named 4C3. This new mAb binds soluble PR3 with a high affinity and membrane-bound PR3 on an epitope close to the PR3 hydrophobic patch and in the vicinity of the active site. 4C3 is able to bind FcγRIIA and FcγRIIIB and has a G2F glycosylation profile on asparagine 297. 4C3 did not induce activation of neutrophils and could inhibit human polyclonal PR3-ANCA-induced activation suggesting that 4C3 is non-pathogenic. This characteristic relies on the recognized epitope on PR3 rather than to the Fc portion properties. The existence of non-pathogenic PR3-ANCA, which do not activate neutrophils, could explain the persistence of high PR3-ANCA levels in some GPA patients in remission and why PR3-ANCA would not predict relapse. Finally, these results offer promising perspectives particularly regarding the understanding of PR3-ANCA pathogenicity and the development of new diagnostic and therapeutic strategies in GPA.

Identifiants

pubmed: 33101296
doi: 10.3389/fimmu.2020.573040
pmc: PMC7546423
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0
Antibodies, Monoclonal 0
Biomarkers 0
Epitopes 0
Myeloblastin EC 3.4.21.76

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

573040

Informations de copyright

Copyright © 2020 Granel, Lemoine, Morello, Gallais, Mariot, Drapeau, Musnier, Poupon, Pugnière, Seren, Nouar, Gouilleux-Gruart, Watier, Korkmaz and Hoarau.

Références

Front Immunol. 2018 Apr 09;9:680
pubmed: 29686675
Clin Exp Immunol. 1999 Oct;118(1):171-9
pubmed: 10540175
Clin Exp Immunol. 1991 Mar;83(3):379-86
pubmed: 1848489
J Mol Biol. 1996 Aug 16;261(2):267-78
pubmed: 8757293
Exp Nephrol. 1995 Jul-Aug;3(4):249-56
pubmed: 8590038
Clin Exp Immunol. 2014 Jun;176(3):363-72
pubmed: 24666336
RMD Open. 2017 Jun 15;3(1):e000449
pubmed: 28955487
J Am Soc Nephrol. 2015 Mar;26(3):537-42
pubmed: 25324502
Curr Rheumatol Rep. 2019 Dec 26;21(12):76
pubmed: 31879818
Semin Immunopathol. 2013 Jul;35(4):411-21
pubmed: 23385856
Clin Exp Immunol. 2002 Sep;129(3):562-70
pubmed: 12197900
Arthritis Rheum. 2011 Jul;63(7):2105-15
pubmed: 21437874
J Immunol. 2018 Nov 15;201(10):3096-3105
pubmed: 30322966
J Autoimmun. 2010 Dec;35(4):299-308
pubmed: 20810247
Arthritis Rheum. 2001 Apr;44(4):921-30
pubmed: 11315931
Kidney Int. 1995 Jun;47(6):1528-36
pubmed: 7643521
J Am Soc Nephrol. 2010 Jul;21(7):1103-14
pubmed: 20448018
J Leukoc Biol. 2006 Dec;80(6):1424-33
pubmed: 16997860
Clin Exp Immunol. 2003 Mar;131(3):528-35
pubmed: 12605707
J Proteome Res. 2015 Apr 3;14(4):1657-65
pubmed: 25761865
Ann Rheum Dis. 2019 May;78(5):709-711
pubmed: 30514699
Front Immunol. 2016 Jun 30;7:256
pubmed: 27446086
Pharmacol Rev. 2016 Jul;68(3):603-30
pubmed: 27329045
Autoimmun Rev. 2014 Jul;13(7):742-50
pubmed: 24657512
Ann Rheum Dis. 2016 Apr;76(4):647-653
pubmed: 27481830
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Am J Respir Cell Mol Biol. 2001 Jun;24(6):747-54
pubmed: 11415941
Autoimmun Rev. 2009 May;8(6):510-4
pubmed: 19185066
J Clin Immunol. 2003 Nov;23(6):460-8
pubmed: 15031633
Curr Chem Genomics. 2009 May 28;3:22-32
pubmed: 20161833
Biochem J. 2002 Sep 15;366(Pt 3):965-70
pubmed: 12088507
Clin Exp Immunol. 2012 Sep;169(3):220-8
pubmed: 22861361
J Immunol. 2010 Jul 1;185(1):387-99
pubmed: 20530264
Pharmacol Rep. 2016 Dec;68(6):1276-1284
pubmed: 27689755
Ann Rheum Dis. 2015 Jan;74(1):177-84
pubmed: 24243925
Front Immunol. 2019 Aug 27;10:1958
pubmed: 31507592
Immunology. 2009 Oct;128(2):236-44
pubmed: 19740380
Kidney Int. 2018 Jul;94(1):139-149
pubmed: 29606398
Clin Chem. 1995 Sep;41(9):1391-7
pubmed: 7656455
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
Kidney Int. 2010 Sep;78(6):590-7
pubmed: 20592714
Proc Natl Acad Sci U S A. 1990 Jun;87(11):4115-9
pubmed: 2161532
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Ann Rheum Dis. 2018 Aug;77(8):1150-1156
pubmed: 29724729
Arthritis Rheum. 2000 Sep;43(9):2025-33
pubmed: 11014352
Autoimmun Rev. 2016 Oct;15(10):978-82
pubmed: 27481040
Clin Exp Immunol. 2002 Jul;129(1):183-90
pubmed: 12100039
Nat Clin Pract Rheumatol. 2006 Apr;2(4):174-5
pubmed: 16932679
JCI Insight. 2017 Jan 26;2(2):e87379
pubmed: 28138552
Ann Rheum Dis. 2011 Mar;70(3):488-94
pubmed: 21109517
MAbs. 2009 Jul-Aug;1(4):332-8
pubmed: 20073133
PLoS One. 2019 Feb 28;14(2):e0213215
pubmed: 30818380
J Clin Invest. 2013 Apr;123(4):1773-83
pubmed: 23549081
Kidney Int. 2001 Jan;59(1):147-59
pubmed: 11135067
Clin Exp Immunol. 1995 Aug;101(2):227-32
pubmed: 7648707
Clin Exp Immunol. 2001 Jan;123(1):170-7
pubmed: 11168015
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
J Leukoc Biol. 2000 Mar;67(3):396-404
pubmed: 10733101
Clin Exp Immunol. 2004 Sep;137(3):451-9
pubmed: 15320893
J Leukoc Biol. 2005 Jan;77(1):33-43
pubmed: 15459232
Autoimmun Rev. 2014 Mar;13(3):313-8
pubmed: 24225075
Nat Rev Rheumatol. 2014 Aug;10(8):463-73
pubmed: 25003769
Ann Rheum Dis. 2007 May;66(5):676-82
pubmed: 17204568
J Biol Chem. 2007 Jan 19;282(3):1989-97
pubmed: 17088257
Arthritis Rheumatol. 2016 Jul;68(7):1700-10
pubmed: 26882078
J Rheumatol. 2005 Nov;32(11):2167-72
pubmed: 16265696
Inflammation. 2000 Dec;24(6):559-69
pubmed: 11128053
Arthritis Res Ther. 2018 Sep 20;20(1):213
pubmed: 30236159
J Leukoc Biol. 2003 Jul;74(1):3-15
pubmed: 12832437
J Immunol. 2016 Jan 15;196(2):607-13
pubmed: 26685205

Auteurs

Jérôme Granel (J)

Plateforme B Cell Ressources (BCR) EA4245, Université de Tours, Tours, France.
Service transversal d'Immunologie Clinique et d'Allergologie, Centre Hospitalier Régional Universitaire, Tours, France.

Roxane Lemoine (R)

Plateforme B Cell Ressources (BCR) EA4245, Université de Tours, Tours, France.

Eric Morello (E)

Plateforme B Cell Ressources (BCR) EA4245, Université de Tours, Tours, France.

Yann Gallais (Y)

Plateforme B Cell Ressources (BCR) EA4245, Université de Tours, Tours, France.

Julie Mariot (J)

Plateforme B Cell Ressources (BCR) EA4245, Université de Tours, Tours, France.

Marion Drapeau (M)

Plateforme B Cell Ressources (BCR) EA4245, Université de Tours, Tours, France.

Astrid Musnier (A)

MAbSilico SAS, Domaine de l'Orfasière, Nouzilly, France.

Anne Poupon (A)

Physiologie de la Reproduction et des Comportements, INRA UMR 0085, CNRS UMR 7247, Université de Tours, Tours, France.

Martine Pugnière (M)

Institut de Recherche en Cancérologie, Institut Régional du Cancer, INSERM U1194, Université Montpellier, Montpellier, France.

Seda Seren (S)

Centre d'Etude des Pathologies Respiratoires, INSERM, UMR 1100, Tours, France.
Université de Tours, Tours, France.

Dalila Nouar (D)

Service transversal d'Immunologie Clinique et d'Allergologie, Centre Hospitalier Régional Universitaire, Tours, France.

Valérie Gouilleux-Gruart (V)

Université de Tours, Tours, France.
Laboratoire d'Immunologie, Centre Hospitalier Régional Universitaire, Tours, France.

Hervé Watier (H)

Université de Tours, Tours, France.
Laboratoire d'Immunologie, Centre Hospitalier Régional Universitaire, Tours, France.

Brice Korkmaz (B)

Centre d'Etude des Pathologies Respiratoires, INSERM, UMR 1100, Tours, France.
Université de Tours, Tours, France.

Cyrille Hoarau (C)

Plateforme B Cell Ressources (BCR) EA4245, Université de Tours, Tours, France.
Service transversal d'Immunologie Clinique et d'Allergologie, Centre Hospitalier Régional Universitaire, Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH